The new Dutch foundation that has criticized the pricing of Leadiant’ Biosciences’ orphan drug CDCA on Sept. 7 will file a formal request with the Dutch competition authority asking it to either fine the company or take some other action over what it calls the “exorbitant price the company is asking.”
Leadiant’s CDCA product, which has EU approval for the treatment of the rare genetic disease cerebrotendinous xanthomatosis (CTX), is currently...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?